AstraZeneca announced promising results from a Phase III trial designed to determine the effectiveness of Lynparza (olaparib) tablets in the treatment of advanced ovarian cancer.
Results from the trial demonstrated a statistically-significant improvement of survival (PFS) among patients treated with Lynparza compared to a placebo, a release stated.
The median PFS in the Lynparza arm of SOLO-2 substantially exceeded that observed in the Phase II maintenance study in patients with platinum-sensitive relapsed ovarian cancer, according to AstraZeneca.
Sean Bohen, executive vice president, global medicines development and chief medical officer at AstraZeneca, said: “We are pleased with the robust improvement in progression-free survival demonstrated by Lynparza in the SOLO-2 trial. We will work with regulatory authorities to make Lynparza tablets available as quickly as possible to patients with ovarian cancer. We remain committed to investigating the full potential of Lynparza, both as monotherapy and in combinations, and to identifying all patients who may benefit from this important medicine.”
The positive results follow the Fast Track Designation for Lynparza by the Food and Drug Administration earlier this year.
Worldwide, ovarian cancer is the seventh most commonly diagnosed cancer and the eighth most common cause of cancer death in women.
